



DR HABEEBULLAH LIFE SCIENCES LIMITED

(Formerly Known as PC Products India Limited)

To,

Date: 17/11/2017

- 1) BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
- 2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E), Mumbai – 400 098
- 3) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanand College,
Panjara Pole, Ambawadi, Ahmedabad – 380 015

Sub: Outcome of Board Meeting under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Company's Letter dated Saturday, 11th November, 2017

Further to our above referred letter, this is to inform Exchange that the Board of Directors of the Company at its meeting held today, Friday, the 17th day of November, 2017 at Registered Office, have approved and taken on record the following:

1. Allotment of 8,00,000 Equity Shares and Allotment of 27,50,000 Convertible Equity Share Warrants on Preferential Basis to Non-Promoters of the Company; upon receiving of In-principle approvals BSE Limited on Friday, 03rd November, 2017 and Metropolitan Stock Exchange of India Limited on Friday, 10th November, 2017.


List of Allottees:

S. No.	Name (PUBLIC CATEGORY)	Equity Shares	Convertible Equity Share Warrants
1	Mr. Kalidhindi Janakirama Raju (NRI)	4,00,000	--
2	Ms. Kalidhindi Rejeswari Harika (PIO)	4,00,000	--
3	Mr. M. Sarvothama Reddy	--	6,00,000
4	Ms. M. Neela Reddy	--	6,25,000
5	Mr. M. Srinivas Chaitanya	--	3,00,000
6	Ms. M. Prabha Sameera	--	6,00,000
7	Ms. Nikita Korupolu	--	3,00,000
8	Mr. Ravi Mandava	--	1,00,000
9	Mr. Mohan Reddy CV	--	75,000
10	Ms. C. Suguna	--	50,000
11	Ms. Anita Lakkadi	--	1,00,000
TOTAL		8,00,000	27,50,000

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad – 500048, TS, India
Corp. Off : Villa 11, Phase 1, Vasudeva Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad – 500008, TS, India
CIN No : L85110TG1996PLC099198
Contact No : 040 – 2970 3333, +91 – 90300 57370

E-Mail : pcproductsindia@gmail.com

Website : www.drhlsl.com




2. Issue of 10,00,000 Convertible Equity Share Warrants on Preferential basis to Promoters of the Company.
3. 1/2017-18 Postal Ballot Notice to be sent to the Shareholders of the Company seeking their Consent for the following:
 - a) Ratification of Disclosure of details of Pre and Post issue Shareholding of proposed allottees in the Explanatory Statement, who are the beneficial owners in respect of allotment of 27,50,000 Convertible Equity Share Warrants on Preferential basis under Non-Promoter Category.
 - b) Issue of 10,00,000 Convertible Equity Share Warrants On Preferential Basis to the Promoters.
 - c) To Authorize Board of Directors to enhance the Investment limits under Section 186 of Companies Act, 2013.
 - d) To Borrow Money (ies) for the purpose of business of the Company and grant powers to Board.
 - e) Creation of Charges on the Movable and Immovable Properties of the Company, both present and future, in respect of borrowings.
4. Standalone Unaudited Financial Results for the **Quarter II and Half Year ended 30th September, 2017** along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.
5. Termination of Master Collaborative Agreement entered with the Subsidiary of the Company, Krisani Bio Sciences Private Limited (KBSPL) dated Saturday, 25th March, 2017 to further develop the Molecule KB-LS-001: CYSTEAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NASH.
6. Incorporation of 100% Wholly Owned Subsidiary in India or Overseas.
7. Appointment of Mr. S. Sarveswar Reddy, Practicing Company Secretary, to act as a scrutinizer to conduct and scrutinize the e-voting and Physical Ballot process in a fair and transparent manner.

The meeting commenced at 3.00 PM and concluded at 6.00 PM.

Request you take the same on records.

Thanking you.

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)



Encl: as above



DR HABEEBULLAH LIFE SCIENCES LIMITED

(Formerly Known as PC Products India Limited)

DISCLOSURE OF PARTICULARS RELATING TO PREFERENTIAL ISSUE OF SHARE WARRANTS

PARTICULARS	DESCRIPTION
Type of Securities proposed to be issued	CONVERTIBLE SHARE WARRANTS INTO EQUITY SHARES
Total No. of Securities and Amount for which Securities will be issued	10,00,000 Share Warrants to Promoters Issue Price – Rs. 20.00/- Face Value – Rs. 10.00/- Premium – Rs. 10.00/-
Details of Investors (Name and No. of Warrants)	Promoters – 1. Dr. Mohammed Aejaz Habeeb – 5,00,000 2. Dr. Syed Ameer Basha Paspala – 5,00,000

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)

Place: Hyderabad

Date: 17/11/2017




DR HABEEBULLAH LIFE SCIENCES LIMITED

(Formerly Known as PC Products India Limited)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER, 2017					
Particulars	INR in Lacs				
	Quarter Ended			Half Year Ended	
	30/9/2017	30/9/2016	30/6/2017	30/9/2017	30/9/2016
	UnAudited	UnAudited	UnAudited	UnAudited	UnAudited
I Revenue from Operations	14.95	79.65	2.55	17.5	110.92
II Other Income	-	0.03	-	-	1.21
III Total Revenue (I+II)	14.95	79.68	2.55	17.5	112.13
IV Expenses					
Cost of Material Consumed	0.56	-	-	0.56	-
Purchase of Stock-in-trade	-	78.09	-	-	108.74
Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-	-
Employee Costs	16.64	1.65	22.19	38.83	3.3
Employee benefits expense	1.18	-	-	1.18	-
Finance Costs	-	-	-	-	-
Depreciation and Amortisation expense	-	-	-	-	-
Other Expense	6.28	2.47	11.17	17.45	6.84
Total Expenses	24.66	82.21	33.36	58.02	118.88
Profit/(Loss) from before Exceptional Items and tax (I-IV)	-9.71	-2.53	-30.81	-40.52	-6.75
VI Exceptional Items	-	-	-	-	-
VII Profit/(Loss) before tax (V-VI)	-9.71	-2.53	-30.81	-40.52	-6.75
VIII Tax Expense:					
Current Tax	-	-	-	-	-
Deferred Tax	-	-	-	-	-
IX Profit/ (Loss) for the period from Continuing operations (VII-VIII)	-9.71	-2.53	-30.81	-40.52	-6.75
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII Profit/ (Loss) for the period (IX+XII)	-9.71	-2.53	-30.81	-40.52	-6.75
XIV Other Comprehensive Income A)	-	-	-	-	-
(i) Items that will not be reclassified to profit or loss (ii)					
Income Tax related to items that will not be reclassified to profit or loss					
B) (i) Items that will be reclassified to profit or loss (ii)					
Income Tax relating to items that will be reclassified to profit or loss					
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	-9.71	-2.53	-30.81	-40.52	-6.75
XVI Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)	-0.09	-0.05	-0.30	-0.40	-0.13
1) Basic 2)					
Diluted					
XVII Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)	-	-	-	-	-
1) Basic 2)					
Diluted					
XVIII Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)	-0.09	-0.05	-0.30	-0.40	-0.13
1) Basic 2)					
Diluted					
XIX Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1025.87	538.81	1025.87	1025.87	538.81

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad – 500048, TS, India
 Corp. Off : Villa 11, Phase I, Vasudeva Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad – 500008, TS, India
 CIN No : L85110TG1996PLC099198
 Contact No : 040 – 2970 3333, +91 – 90300 57370
 E-Mail : pcproductsindia@gmail.com
 Website : www.drhlsl.com



Statement of Assets and Liabilities

(INR. in Lakhs)

Particulars	Half Year Ended 30/09/2017 Unaudited
ASSETS	
1 Non Current Assets	
a Property, Plant and Equipments	1.16
b Capital Work In Progress	-
c Investment Prpoerty	-
d Goodwill	-
e Other Intangible Assets	-
f Intangible Assets under development	29.68
g Biological assets other than bearer plants	-
h Financial Assets:	
Investments	487.06
Trade Receivables	-
Loans	-
Others	-
Loans	-
Others	-
i Deferred Tax Assets (net)	-
Other Non Current Assets	-
Total Non Current Assets	517.90
2 Current Assets	
a Inventories	0.99
b Financial Assets:	
Investments	-
Trade Receivables	308.45
Cash and Cash Equivalents	3.73
Bank balances other than above	3.61
Loans	22.00
Others	2.38
c Current Tax Assets (net)	-
d Other Current Assets	0.85
Total Current Assets	342.01
Total Assets	859.91
EQUITY AND LIABILITIES	
1 Equity	
a Equity Share Capital	1,025.87
b Other Equity	-
c Reserves & Surplus	(230.60)
Total - Equity	795.27
2 Liabilities	
Non Current Liabilities	
a Financial Liabilities	
Borrowings	37.25
Trade Payables	-
Other Financial Liabilities	-
b Provisions	-
c Deferred Tax Liabilities (net)	-
d Other Non Current Liabilities	-
Total Non Current Liabilities	37.25
Current Liabilities	
a Financial Liabilities:	
Borrowings	-
Trade Payables	4.33
Other Financial Liabilities	-
b Other Current Liabilities	4.33
c Provisions	18.73
d Currenr Tax Liabilities (net)	-
Total Current Liabilities	27.39
Total - Equity and Liabilities	859.91



For DR HAEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju

K. Krishnam Raju
Executive Chairman (DIN 00874650)

Place: Hyderabad
Date: 17/11/2017

Notes:

- 1 Beginning April, 2017; the Company has for the first time adopted the Indian Accounting Standards (Ind AS) with a transition date of April, 2016 and accordingly these financial statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder.
- 2 The format for the Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.1(iii) has been availed. Hence, Figures of corresponding previous quarter and previous year have not been provided.
- 3 There is a possibility that these quarterly financial results may require adjustment before compiling the final Ind AS financial statements as of and for the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from retrospective application of certain Ind AS as permitted under Ind AS 101.
- 4 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 5A **The Company has also started trial run in Molecular Diagnostics and expecting to launch the same by Quarter IV of the Financial Year 2017-18.**
- 5B **During the Quarter II, the Company has filed 1 Patent - A Neural Conduit to reconstitute and regenerated or damaged Nervous System.**
- 5C **The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.**
- 5D **Termination of Master Collaborative Agreement entered with the Subsidiary of the Company, Krisani Bio Sciences Private Limited (KBSPL) dated Saturday, 25th March, 2017 to further develop the Molecule KB-LS-001: CYSTEAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NASH.**
- 6 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Friday, 17th November, 2017.
- 7 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 30th September, 2017. The Ind AS Complaint figures for the Corresponding previous Quarter ended 30th September, 2016 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 8 The results are also available on the website of the Company www.drhsl.com
- 9 Reconciliation between Financial Results previously reported (referred to as PREVIOUS GAAP) and Ind AS for the Quarter ended 30th September, 2016 (As per paragraph 32 of Ind AS 101)

Particulars	Quarter Ended 30/09/2017 (Rs. In Lacs)	Half Year Ended 30/09/2016 (Rs. In Lacs)
Net Profit as per previous GAAP	-9.71	-6.75
Increase in profit due to:		
Fair Value Impact for financial instrument	NIL	NIL
Net Profit after Ind AS (After Tax)	-9.71	-6.75
Other Comprehensive Income	NIL	NIL
Total Comprehensive Income under Ind AS	-9.71	-6.75

For DR HAEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)

Place : Hyderabad
Date : 17/11/2017



N. M. KHATAVKAR & CO.

CHARTERED ACCOUNTANTS

Cell : 94488 37388

Tele / Fax : 0836 2258841

Email : nandrajkhataavkar@yahoo.com

nmk1365@gmail.com

Limited Review Report

Review Report to Board of Directors

Dr Habeebullah Life Sciences Limited, Hyderabad, Telangana.

We have reviewed the accompanying Statement of **Unaudited Standalone Financial Results** of Dr Habeebullah Life Sciences Limited (Formerly Known as PC Products India Limited) for the **Period/Quarter II Ended 30th September 2017**. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016; including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hubli

Date: 17/11/2017



For N.M. Khataavkar & Co.,
Chartered Accountants
For N. M. Khataavkar & Co.,
Chartered Accountant

(Khataavkar N. M.)

Proprietor

Membership Number : 206569

Firm Regn No. 007939 S

N.M. Khataavkar Proprietor

Membership No. 206569

Firm Regd No. 007939S

Divate Complex, Club Road, Hubli - 580029.